Global High-Priority Regulatory Events — March 21, 2026

Successful Open Offer triggers complete board and management overhaul with new Chairman & MD Vikkas Bansal (25+ years die casting experience), signaling fresh strategic direction post-change in control

Resigning directors (incl. MD, CFO, Promoter Director) cite only Open Offer as reason, no other material issues, clearing path for new leadership without hidden concerns

₹1.56L NSE penalty fully reversed via March 20, 2026 communication (originally Aug 30, 2025), resolving Reg 17(1A) non-compliance with no ongoing costs

Prompt payment of ₹6.60L fines (₹3.30L each BSE/NSE + GST) on March 15, 2026 for late Q results under Reg 33, mitigating escalation risk

CIRP admitted on ₹7.47 Cr operational debt (₹6.19 Cr principal + ₹1.28 Cr interest at 18% p.a. from Nov 7, 2023 default), debtor admitted claim in full

5th CoC meeting March 21, 2026 accepts late resolution plans (up to midnight March 17), but no quantified approvals signal prolonged CIRP uncertainty

₹57,408 Cr auction across 22 states/UTs on March 24, 2026 (new yields + re-issues), up to 10% non-competitive allocation offers liquidity play amid equity distress

New appointees (Tarun Jain Exec Dir, Priyanka CFO, 4 Independents) affirm no disqualifications under Companies Act Sec 164, bolstering governance post-overhaul

Penalty reversal for Q2 FY26 (ended June 30, 2025) non-compliance removes overhang vs. peers facing persistent fines (e.g., Gujarat Kidney)

RP Najeeb T P chairs CoC with focus on CIRP costs and interim finance needs, indicating creditor engagement without immediate liquidation

Moratorium under IBC Sec 14 halts recoveries/asset transfers, freezing downside but capping upside until resolution

No further financial/operational impact from March 17, 2026 notices, fines paid pre-notice suggesting proactive compliance

NCLT admits CIRP on March 17, 2026 for ₹7.47 Cr default (from ₹18.36 Cr invoiced, post ₹12.17 Cr payments), moratorium imposes Sec 14 restrictions

Ongoing 5th CoC meeting March 21, 2026 highlights unresolved CIRP costs and plan evaluation needs post NCLT orders (Oct 2025/Jan 2026)

₹6.60L fines for Reg 33 late filing (notices March 17, 2026), signals governance lapses vs. resolved peers like Burnpur

Full resignation of 5 key personnel (MD, CFO, Promoter Dir) effective March 22, 2026 post Open Offer, mixed sentiment on execution risks

Interest at 18% p.a. on ₹6.19 Cr principal from Nov 2023 default (authenticated NeSL Form D) indicates escalating obligations

Late plan acceptance to midnight March 17, 2026 extends uncertainty, no resolutions quantified in March 21 CoC

Repeated notices from BSE/NSE (6:48-7:12 PM March 17) for Q results delay, potential for recurring compliance issues

No insider trading disclosed, but promoter-linked resignations (Amit/Bharat Patel) amid Open Offer may flag promoter exit

Original penalty Aug 30, 2025 for Q1 FY26 Reg 17(1A) reversed, but history of non-compliance warrants monitoring

High ₹57k Cr volume March 24 could pressure yields if competitive bids exceed, impacting state debt pricing

New leadership (Vikkas Bansal 25+ yrs experience) post March 21 board meeting offers turnaround potential in die casting-related ops

Clean slate post ₹1.56L reversal (March 20 NSE comm), undervalued vs. fined peers, low materiality allows focus on core cement ops

₹57,408 Cr auction March 24 (E-Kuber 10:30-11:30 AM competitive), retail access via Retail Direct for yield capture amid equity insolvencies

6 new directors (incl. Woman ID, CFO) effective March 21, 2026 with no Sec 164 issues, positions for post-control value unlock

CoC accepts plans to March 17 midnight, potential for favorable resolution if interim finance secured, distressed pricing entry

Full claim admission in CIRP (₹7.47 Cr), monitor RP Rajesh Jhunjhunwala for plan outcomes post March 17 admission

Immediate fine payment March 15 pre-notices, no impact stated, dip-buy healthcare small-cap at governance bottom

Outperforms fined peer Gujarat Kidney (reversal vs. ₹6.6L payment), sector-relative alpha in cement compliance

Non-executive promoter dir exit tied solely to Open Offer, new unrelated mgmt (except Bansal-Jain) reduces legacy risks

Up to 10% allocation March 24, low-risk entry for fixed income vs. high-risk CIRP equities

2/7 filings (Remedium Lifecare, Radhagobind) in CIRP with ₹7.47 Cr default and ongoing CoC, signaling sector credit crunch post-2023 defaults

Classic Filaments (2 filings) full board overhaul post Open Offer, mixed sentiment but new 25+ yr exp MD vs. no financial trends elsewhere

Cement (Burnpur reversal ₹1.56L) and healthcare (Gujarat ₹6.6L fines) show mixed compliance (1 positive, 1 negative), low materiality but governance drag

RBI SGS ₹57k Cr auction amid equity events provides safe-haven alternative, no YoY auction comps but timely March 24 catalyst

100% key personnel exit at Classic (5 resign, 6 appoint March 21), no insider pledges/holdings but clears path without material reasons [MIXED, MONITOR EXECUTION]

Insolvencies at 10/10, Open Offer 9/10 vs. regs 3-4/10, prioritizing distress over routine in Indian-listed small-caps

Monitor post-March 22 resignations for strategy updates, new MD Vikkas Bansal execution on die casting ops [POST March 22, 2026]

Track Interim RP Rajesh Jhunjhunwala post March 17 NCLT admission, CoC formation on ₹7.47 Cr claim [Q2 2026]

Watch 6th CoC post March 21 meeting for plan approvals/resolutions, NCLT Kolkata timelines [April 2026]

Results and payment March 24-25, 2026; track yields vs. expectations for state debt implications [March 24, 2026]

Further Reg 33 filings post March 17 fines, scrip 544666 for recurrence [Q1 FY27]

Post-reversal NSE comm March 20, monitor Reg 17(1A) adherence in upcoming quarters [Q3 FY26]

Performance of additional directors (Tarun Jain, Priyanka CFO) confirmation, no disqualifications affirmed [AGM 2026]

Sec 14 effects on operations post Nov 2023 default, creditor recoveries frozen [Ongoing through CIRP]